See more : Sky Gold Limited (SKYGOLD.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Indivior PLC (INDV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Indivior PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Crestwood Equity Partners LP (CEQP-P) Income Statement Analysis – Financial Results
- JBG SMITH Properties (JBGS) Income Statement Analysis – Financial Results
- Taihan Electric Wire Co., Ltd. (001440.KS) Income Statement Analysis – Financial Results
- Teikoku Tsushin Kogyo Co., Ltd. (6763.T) Income Statement Analysis – Financial Results
- Chunghwa Telecom Co., Ltd. (2412.TW) Income Statement Analysis – Financial Results
Indivior PLC (INDV)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indivior.com
About Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 884.63M | 777.48M | 689.68M | 815.16M | 959.92M | 1.15B | 968.89M |
| Cost of Revenue | 186.00M | 168.87M | 137.61M | 116.19M | 165.11M | 134.68M | 122.90M | 110.81M |
| Gross Profit | 907.00M | 715.75M | 639.87M | 573.49M | 650.05M | 825.25M | 1.03B | 858.08M |
| Gross Profit Ratio | 82.98% | 80.91% | 82.30% | 83.15% | 79.75% | 85.97% | 89.30% | 88.56% |
| Research & Development | 106.00M | 70.69M | 51.11M | 42.64M | 55.04M | 63.99M | 93.49M | 108.98M |
| General & Administrative | 575.00M | 545.00M | 239.00M | 447.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 236.00M | 218.00M | 192.00M | 202.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 811.00M | 439.86M | 404.96M | 437.05M | 385.25M | 444.14M | 508.40M | 411.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 911.00M | 510.55M | 456.07M | 479.69M | 440.29M | 508.14M | 601.89M | 520.16M |
| Cost & Expenses | 1.10B | 679.43M | 593.68M | 595.88M | 605.40M | 642.82M | 724.79M | 630.97M |
| Interest Income | 43.00M | 18.00M | 1.00M | 7.00M | 24.92M | 16.24M | 7.35M | 0.00 |
| Interest Expense | 37.00M | 29.00M | 26.00M | 24.00M | 20.77M | 29.61M | 51.47M | 51.00M |
| Depreciation & Amortization | 28.00M | 20.62M | 21.62M | 27.72M | 29.08M | 15.28M | 13.66M | 12.82M |
| EBITDA | 68.61M | -44.18M | 233.93M | -128.98M | 214.00M | 310.42M | 436.97M | 149.27M |
| EBITDA Ratio | 6.28% | 25.53% | 26.42% | 17.62% | 29.30% | 34.63% | 38.06% | 36.20% |
| Operating Income | -4.00M | 205.20M | 183.80M | 93.81M | 209.76M | 317.11M | 423.32M | 337.92M |
| Operating Income Ratio | -0.37% | 23.20% | 23.64% | 13.60% | 25.73% | 33.03% | 36.87% | 34.88% |
| Total Other Income/Expenses | 5.00M | -10.00M | -23.00M | -17.00M | -22.85M | -14.00M | -56.00M | -51.00M |
| Income Before Tax | 1.00M | -93.27M | 186.75M | -184.41M | 186.92M | 265.53M | 143.91M | 89.75M |
| Income Before Tax Ratio | 0.09% | -10.54% | 24.02% | -26.74% | 22.93% | 27.66% | 12.53% | 9.26% |
| Income Tax Expense | -1.00M | -41.24M | -14.74M | -26.65M | 47.77M | 2.87M | 82.98M | 57.69M |
| Net Income | 2.00M | -52.04M | 205.00M | -157.76M | 139.15M | 262.67M | 60.92M | 32.05M |
| Net Income Ratio | 0.18% | -5.88% | 26.37% | -22.87% | 17.07% | 27.36% | 5.31% | 3.31% |
| EPS | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| EPS Diluted | 0.01 | -0.37 | 1.31 | -1.08 | 0.92 | 1.75 | 0.41 | 0.22 |
| Weighted Avg Shares Out | 137.31M | 139.01M | 145.66M | 146.57M | 146.05M | 145.43M | 144.23M | 143.97M |
| Weighted Avg Shares Out (Dil) | 141.80M | 139.01M | 154.23M | 146.57M | 151.07M | 150.23M | 149.70M | 148.64M |
INDV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
October 1, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against INDV
Levi & Korsinsky Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming Deadline - INDV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior Lawsuit - INDV
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
Indivior PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
The Schall Law Firm Urges Stockholders To Join A Securities Fraud Case Against Indivior PLC
Contact Levi & Korsinsky by October 1, 2024 Deadline to Join Class Action Against Indivior PLC(INDV)
INDV Shareholders Have Opportunity to Lead Indivior PLC Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Class Action Filed Against Indivior PLC (INDV) Seeking Recovery for Investors - Contact Levi & Korsinsky
Source: https://incomestatements.info
Category: Stock Reports